AIM-HIV PROJECT------------------------Instituto Salud Carlos III



Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH; CAPRISA004 TRAPS team.
J Infect Dis. 2012 Oct 1;206(7):993-1001.

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Omar Z, Miya N, Mlisana K, Maarshalk S, Karim SS.
Antivir Ther. 2013;18(3):301-10.

Acceptability and accessibility of microbicides

An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana.
Abdulai MA, Baiden F, Adjei G, Afari-Asiedu S, Adjei K, Tawiah C, Newton S.
BMC Womens Health. 2012 Nov 1;12:40.

How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community. 
Gafos M, Mzimela MA, Ndlovu HB, McCormack S, McGrath N. 
AIDS Care. 2013;25(5):573-8.

Perspectives of traditional health practitioners on the use of microbicides for the prevention of HIV.
Walwyn D, Maitshotlo B.
Afr J Tradit Complement Altern Med. 2012 Feb 13;9(3 Suppl):24-6. eCollection 2012.

NEWS 01  


Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of menstrual cycle. Read more.    




10/01/2014. The partners of the project and the Scientific Advisory Board attended the Progress Meeting of the project in Madrid.  



October 7-10, 2013. ISCIII and SEPROX presented an oral communication and a poster in the AIDS Vaccine Conference. Read more.


Instituto de Salud Carlos III. 2013. All rights reserved

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 305938.

Web Map  Legal AdviceAccesibility | Contact

cea unisr seprox biotech IscIII